Sep

15

A new form of human growth hormone (hgh) is being used to treat a rare blood disorder:

Teva Pharmaceutical Industries Ltd. yesterday obtained marketing authorization from the European Commission Directorate General for Enterprise and Industry for TevaGrastim, a human granulocyte colony stimulating factor (G-CSF) product. It is a biosimilar product of Neupogen Filgrastim, a recombinant DNA treatment for chemotherapy-induced neutropenia (a blood disorder) made by Amgen Inc.

Read more about the benefits of HGH and the top selling HGH product on the market today! Click here.

Read the entire hgh/blood disorder article by clicking here.

Recommended Links

GET YOUR FREE HGH &
ANTI-AGING REPORT!